Companies › BioMarin Pharmaceutical
9 active drug programs in 18 registered trials: 8 Phase 2, 4 Phase 3, 4 Phase 1, 2 Phase 4; Metabolic and endocrine, Other, Hematology, Immunology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pegvaliase Phenylalanine ammonia-lyase (PAL) enzyme - degrades phenylalanine to ammonia and trans-cin | PAH | Phase 4 | Phenylketonuria; Phenylketonuria (PKU) | Sep 2027 |
| Palynziq Pegvaliase (PEGylated recombinant phenylalanine ammonia-lyase) | PAH | Phase 4 | Phenylketonuria | – |
| Vosoritide Atrial natriuretic peptide receptor B binding agent | NPR2 | Phase 3 | Hypochondroplasia; Achondroplasia; Noonan Syndrome; Idiopathic Short Stature … | Mar 2027 |
| valoctocogene roxaparvovec Coagulation factor IX exogenous protein | F9 | Phase 3 | Hemophilia A | Mar 2029 |
| BMN 333 C-type natriuretic peptide (CNP) receptor agonist | – | Phase 2 | Achondroplasia | Jun 2029 |
| BMN 351 Antisense oligonucleotide targeting DMD exon 51 | – | Phase 1 | Duchenne Muscular Dystrophy | Apr 2027 |
| BMN 307 AAV gene therapy delivering phenylalanine hydroxylase (PAH) gene | PAH | Phase 1 | Phenylketonuria (PKU) | Dec 2027 |
| BMN 331 AAV5-based gene therapy expressing wild-type human C1 Esterase Inhibitor (hC1-INH) | – | Phase 1 | Hereditary Angioedema | Nov 2028 |
| BMN 349 | – | Phase 1 | Alpha 1-Antitrypsin Deficiency | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06455059 | Vosoritide | Phase 3 | Hypochondroplasia | Other | Aug 2026 |
| NCT06780332 | Palynziq | Phase 4 | Phenylketonuria | Metabolic and endocrine | Aug 2026 |
| NCT06738017 | BMN 349 | Phase 1 | Alpha 1-Antitrypsin Deficiency | Metabolic and endocrine | Aug 2026 |
| NCT06668805 | Vosoritide | Phase 2 | Noonan Syndrome | Other | Mar 2027 |
| NCT06280209 | BMN 351 | Phase 1 | Duchenne Muscular Dystrophy | Neurology | Apr 2027 |
| NCT07477691 | Pegvaliase | Phase 4 | Phenylketonuria | Metabolic and endocrine | Sep 2027 |
| NCT05270837 | Pegvaliase | Phase 3 | Phenylketonuria (PKU) | Metabolic and endocrine | Oct 2027 |
| NCT04554940 | Vosoritide | Phase 2 | Achondroplasia | Other | Dec 2027 |
| NCT02724228 | Vosoritide | Phase 2 | Achondroplasia | Other | Dec 2027 |
| NCT04480567 | BMN 307 | Phase 1 | Phenylketonuria (PKU) | Metabolic and endocrine | Dec 2027 |
| NCT07126262 | Vosoritide | Phase 2 | Hypochondroplasia | Other | Jun 2028 |
| NCT05121376 | BMN 331 | Phase 1 | Hereditary Angioedema | Immunology | Nov 2028 |
| NCT06224907 | valoctocogene roxaparvovec | Phase 3 | Hemophilia A | Hematology | Mar 2029 |
| NCT07441876 | BMN 333 | Phase 2 | Achondroplasia | Other | Jun 2029 |
| NCT03424018 | Vosoritide | Phase 3 | Achondroplasia | Other | Jun 2031 |
| NCT04219007 | Vosoritide | Phase 2 | Short Stature | Metabolic and endocrine | Jun 2035 |
| NCT06382155 | Vosoritide | Phase 2 | Idiopathic Short Stature | Metabolic and endocrine | Dec 2036 |
| NCT03989947 | Vosoritide | Phase 2 | Achondroplasia | Other | May 2038 |
Cash and short-term investments of $736m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
CSL Behring PTC Therapeutics Chongqing Peg-Bio Biopharm NGGT Agios Pharmaceuticals NGGT (Suzhou) Biotechnology Pfizer Roche Shanghai Xinzhi BioMed IntraBio
PTC Therapeutics Viking Therapeutics CSPC Ouyi Pharmaceutical Amylyx Pharmaceuticals Rhythm Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.